Arcus biosciences completes patient enrollment in phase 3 trial evaluating a domvanalimab-containing regimen in first-line metastatic upper gi cancers

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced the completion of patient enrollment for star-221, a phase 3 study in collaboration with gilead sciences, evaluating the combination of the fc-silent anti-tigit antibody domvanalimab plus the anti-pd-1 monoclonal antibody zimberelimab and chemotherapy in patients.
RCUS Ratings Summary
RCUS Quant Ranking